The Low DoseThe GLP-1 price desk
Briefing

Lemonaid Health vs TrimRx

$348/mo against $399/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. Lemonaid Health costs $348 a month and TrimRx costs $399, a difference of $51 a month or about $612 a year. The desk reads it as follows.

Lemonaid Health is established platform with multi-month discounts. TrimRx is all-inclusive compounded pricing. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. Lemonaid Health advertises $229 and bills $348; TrimRx advertises $349 and bills $399. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

LemonaidTrimRx
Advertised$229$349
Billed$348$399
Gap+$119+$50
Per year, billed$4,176$4,788

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

On every attribute we track these two behave identically — same answer on dose pricing, commitment, pharmacy disclosure, formats, insurance and what the price includes. When that happens the decision really is just the monthly figure, and Lemonaid Health is $51 a month cheaper.

What each puts on the record: Lemonaid Health

  • A compounded tirzepatide microdose tier is listed at $199/month.
  • Medication is billed separately from the membership.

Where it wins: Multi-month plans cut the medication price substantially. Watch for: Add $49/month to every price you are quoted. The advertised $129 is a programme floor, not the injection cost.

What each puts on the record: TrimRx

    Where it wins: One price covers consultation, medication and supplies. Watch for: Read the ongoing rate on the checkout screen, not the landing page. Reported billing is $399/month.

    In each one’s favour

    Lemonaid Health.

    • Multi-month plans cut the medication price substantially.
    • An established platform with a long operating history in telehealth.

    TrimRx.

    • One price covers consultation, medication and supplies.
    • No separate membership fee.

    Lemonaid Health scores higher overall at 3.5 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

    The desk’s call

    The board says Lemonaid Health. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

    The verdict

    On the board, Lemonaid Health at $348 a month is the more defensible choice on arithmetic alone. TrimRx earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Lemonaid Health and TrimRx.

    How they sit against everyone else

    ProgrammeAdvertisedBilledGapVs board floor
    Coreage Rx$149$199+$50+$74/mo
    Trimi$125$125none—
    Ozari Health$125$125none—
    Fifty 410$133$133none+$8/mo

    More from the desk

    • Lemonaid Health tirzepatide review

      Advertised at $229, billed at $348. Position 12 of 18 on our board.

    • TrimRx tirzepatide review

      Advertised at $349, billed at $399. Position 13 of 18 on our board.

    • How to spot a bad seller

      The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

    • The twelve-month cost

      Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

    • Cheapest right now

      Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

    Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure